Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/26/2008

stock-based compensation

expense $3,091 $5,465 $9,590 $18,283

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2006 and 2007

(In thousands, except for share and per share data)

December 31, December 31,

2006 2007

ASSETS

Current assets:

Cash and cash equivalents $89,162 $228,343

Short-term investments 199,685 357,251

Accounts receivable, net 14,670 16,976

Advances to BioMarin/Genzyme LLC 1,596 2,087

Inventory 25,075 32,445

Other current assets 4,036 7,195

Total current assets 334,224 644,297

Investment in BioMarin/Genzyme LLC 31,457 44,881

Property, plant and equipment, net 55,466 76,818

Intangible assets, net 11,655 9,596

Goodwill 21,262 21,262

Restricted cash 1,731 2,889

Other assets 7,641 15,536

Total assets $463,436 $815,279

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities $32,166 $49,907

Current portion of acquisition obligation,

net of discount 6,787 6,309

Current portion of deferred rev
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Holdings, Inc. (NYSE Amex: BONE ), a ... antimicrobial coatings for medical applications, has been invited to present ... be held at the Four Seasons Hotel in Boston, Massachusetts ... Guy Cook, and CFO, John Gandolfo, are scheduled to present ...
... MINNEAPOLIS, Aug. 24, 2011 Cellectis bioresearch, the ... Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in ... development and license agreement on the creation of ... accordance with biosafety and animal well-being requirements, large ...
... Pa., Aug. 24, 2011 Kibow Biotech, Inc. today ... and marketing agreement with the current licensing partner specializing ... 100% natural, probiotic dietary supplement indicated for the reduction ... severe renal failure. Developed by Kibow, Azodyl™ has been ...
Cached Biology Technology:Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , a ... will showcase its EyeLock ID technology integrated in a 3D ... Oak Ridge National Laboratory (ORNL) at the 2015 ... authentication technology is being used to validate the driver and ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... recognition is the foundation of the body,s immune response ... DC-SIGN is part of the immune system, and recognizes ... and HIV. How the molecule binds to pathogens has ... led by University of Illinois chemist Deborah Leckband show ...
... Nanostructured materials have garnered great interest worldwide due ... structural, medical and consumer applications. Singapore,s ... a new environmentally friendly method to synthesize a ... synthesis has been recently published in Nature ...
... The University of Arizona College of Pharmacy has ... half of drug pairs with potentially dangerous drug-drug ... of the high number of drugs Americans take: ... each physician office visit. A synopsis of ...
Cached Biology News:Flexible neck in cell-receptor DC-SIGN targets more pathogens 2Facile synthesis of nanoparticles with multiple functions advanced in Singapore 2UA pharmacy research shows prescribers miss potentially dangerous drug pairs 2
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
IC50: 190 pg/ml · Limit of detection: 60 pg/ml...
Request Info...
Request Info...
Biology Products: